A study published in The Lancet journal states that benralizumab injection therapy for asthma and COPD is more effective than corticosteroid tablets, reducing the need for subsequent treatments for patients. This is the first new treatment for asthma and COPD patients in 50 years. Benralizumab is a type of anti-inflammatory drug developed by Astrazeneca in the usa, which can directly, quickly, and almost completely eliminate eosinophils within 24 hours to reduce lung inflammation.